exagen-logo-black.png
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12. Dezember 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...
exagen-logo-black.png
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
14. November 2024 16:30 ET | Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
exagen-logo-black.png
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
13. November 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following...
exagen-logo-black.png
Exagen Inc. Reports Third Quarter 2024 Results
12. November 2024 08:00 ET | Exagen Inc.
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
29. Oktober 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
21. Oktober 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
04. September 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
05. August 2024 08:00 ET | Exagen Inc.
CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
02. August 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
01. August 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of...